Akademik Veri Yönetim Sistemi
JOURNAL OF MOLECULAR STRUCTURE, cilt.1352, 2026 (SCI-Expanded, Scopus)
Cancer remains one of the leading causes of death worldwide, making the search for effective anticancer agents a critical area of research. In recent years, ruthenium-based compounds have gained significant attention due to their potential as novel candidates for cancer treatment. This report aims to explore the synthesis and anticancer properties of the Ru(II)oxothiazolidine complexes. All complexes have been prepared from ligands containing hydrazinyl-oxothiazolidine moiety and [RuCl2(p-cymene)]2 substrate. The basic skeleton of the complexes is justified with 1H-, 13C-NMR, and FTIR spectroscopic methods. The proposed structures of the complexes were further confirmed with elemental analysis. The crystal structure of the complex 2a has been determined by using single-crystal X-ray diffraction. Asymmetric unit of structure contains two crystallographically independent molecules, dichloromethane and two chloride anions. All complexes exhibited strong activity against MCF-7 (breast cancer) and HCT-116 (colon cancer) cancer cell lines better than standard anticancer drug cisplatin. The complex 2a showed the highest anticancer efficacy against MCF-7 (IC50: 13.89 mu M) and HCT-116 (IC50: 14.02 mu M). DNA binding study also demonstrates that all complexes have an interaction ability to DNA. Ethidium bromide fluorescence quenching assay revealed moderate DNA binding for complex 2a suggesting partial intercalation or groove binding with ct-DNA. Meanwhile, molecular docking simulations of potent rutheniumbased oxothiazolidine complexes (1a, 1c, and 2a) against breast (MCF-7) and (1a, 1c, and 2a) colon (HCT116) cancer cell models were carried out. The findings suggest that complex 2a is the best candidate complex for both cancers. Furthermore, complexes 1a and 1c demonstrated potent cytotoxic activity against MCF-7 breast cancer cells, whereas complexes 1b and 2d exhibited significant cytotoxic effects against HCT-116 colon cancer cells.